Abstract: Objective:To compare the efficacy and adverse effects of a regimen of etoposide and cisplatin with those of etoposide and lobaplatin in treating small-cell lung cancer.Methods:Data from 42patients with small-cell lung cancer who received initial treatment in our hospital during the period between May 2006 and October 2008 were retrospectively ana -lyzed. Of these patients, 23were at the limited-stage disease and 19at the extensive-stage disease. Twenty-three of the to -tal patients were assigned to the Lobaplatin Group: Lobaplatin was given at 30mg/m2 i.v on day 1, etoposide was given at 100 mg/m2 i.v from day 1 to day 3. The remaining 19patients were assigned to the Cisplatin Group: Cisplatin was given at 25mg/m2 and etoposide was given at100 mg/m2 i.v from day 1 to day 3. The dosage and usage of etoposide were the same in the 2 groups. Comparisons were conducted for efficacy, time to progression of disease (PD), 1-year survival rate, and ad -verse effects between the patients of the two groups. Results:All42patients were evaluated for curative effect. In the loba -platin group, complete remission (CR) was observed in 8 of the cases, partial remission (PR) was observed in8, stable dis -ease (SD) was observed in 4 and PD was observed in3. In the cisplatin group, CR was seen in 8 of the cases, PR was seen in 7, SD was seen in 2 and PD was seen in 2. The overall response rate (ORR) was 69.6% in the lobaplatin group and 78.9% in the cisplatin group. There was no statistical difference in the response rate between the two groups (P= 0.726 ). The median time to PD was 8 months for the lobaplatin group and 10months for the cisplatin group (P= 0.553 ), and the one-year survival rates were 66.6% and 64.3% (P=0.973 ), respectively. There were no statistical differences in the time to PD or one-year survival rate. The main adverse reaction included bone-marrow depression and nausea/vomiting. The in -cidence of grade- Ⅲ~ Ⅳthrombocytopenia was higher in the lobaplatin group than in the cisplatin group (P=0.239 ), without statistically significant differences between the two groups. The incidence of nausea/vomiting was higher in the cisplatin group than in the lobaplatin group ( P=0.043 ). Conclusion:The etoposide plus lobaplatin regimen is an effective and low-tox -icity chemotherapy in initial treatment of small-cell lung cancer. The curative effects of the two regimens are similar, warrant -ing further clinical research.